Trial · NCT07891650
Personalized Intermittent Theta Burst Stimulation for Cognitive Impairment Related to Cerebral Small Vessel Disease
NCT07891650, Not applicable, Not yet recruiting, Xuanwu Hospital, Beijing
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Personalized Intermittent Theta Burst Stimulation for Cognitive Impairment Related to Cerebral Small Vessel Disease. Trials, record NCT07891650. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07891650
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Personalized Intermittent Theta Burst Stimulation for Cognitive Impairment Related to Cerebral Small Vessel Disease
- NCT number
- NCT07891650
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 160 participants, estimated
- Lead sponsor
- Xuanwu Hospital, Beijing
- Conditions
- Cerebral Small Vessel Disease, Vascular Cognitive Impairment
- Interventions
- Active Personalized Intermittent Theta Burst Stimulation, Sham Personalized Intermittent Theta Burst Stimulation
- First posted
- 2026-10-23
- Last updated
- 2026-10-23
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change From Baseline in Montreal Cognitive Assessment (MoCA) Total Score at Week 24 | Baseline and week 24 (end of treatment) | The Montreal Cognitive Assessment (MoCA) assesses global cognitive function. Total scores range from 0 to 30, with higher scores indicating better cognitive function. Change will be calculated as the week 24 total score minus the baseline total score. A positive change indicates improvement. |
| Secondary | Change From Baseline in Montreal Cognitive Assessment (MoCA) Total Score at Three Months After Treatment | Baseline and three months after completion of the 24-week treatment period | The Montreal Cognitive Assessment (MoCA) assesses global cognitive function. Total scores range from 0 to 30, with higher scores indicating better cognitive function. Change will be calculated as the three-month post-treatment follow-up total score minus the baseline total score. A positive change indicates improvement. |
| Secondary | Change From Baseline in Mini-Mental State Examination (MMSE) Total Score | Baseline, week 24 (end of treatment), and three months after completion of treatment | The Mini-Mental State Examination (MMSE) assesses global cognitive function. Total scores range from 0 to 30, with higher scores indicating better cognitive function. Changes will be calculated separately as the total score at each post-baseline assessment minus the baseline total score. Positive changes indicate improvement. |
| Secondary | Change From Baseline in Clinical Dementia Rating (CDR) Global Score | Baseline, week 24 (end of treatment), and three months after completion of treatment | The Clinical Dementia Rating (CDR) global score assesses the severity of cognitive and functional impairment. Possible scores are 0, 0.5, 1, 2, and 3, with higher scores indicating greater impairment. Changes will be calculated separately as the global score at each post-baseline assessment minus the baseline global score. Negative changes indicate improvement. |
| Secondary | Change From Baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB) Score | Baseline, week 24 (end of treatment), and three months after completion of treatment | The Clinical Dementia Rating-Sum of Boxes (CDR-SB) is calculated by summing ratings across six cognitive and functional domains. Scores range from 0 to 18, with higher scores indicating greater impairment. Changes will be calculated separately as the score at each post-baseline assessment minus the baseline score. Negative changes indicate improvement. |
| Secondary | Change From Baseline in Activities of Daily Living (ADL) Score | Baseline, week 24 (end of treatment), and three months after completion of treatment | Activities of daily living will be assessed using the ADL scale. Changes will be calculated separately as the score at each post-baseline assessment minus the baseline score. |
| Secondary | Change From Baseline in Auditory Verbal Learning Test (AVLT) Scores | Baseline, week 24 (end of treatment), and three months after completion of treatment | Verbal learning and memory will be assessed using the Auditory Verbal Learning Test (AVLT). Changes will be calculated separately as each prespecified AVLT score at each post-baseline assessment minus its corresponding baseline score. |
| Secondary | Change From Baseline in Trail Making Test (TMT) Performance | Baseline, week 24 (end of treatment), and three months after completion of treatment | Performance on the Trail Making Test (TMT) will be assessed. Changes will be calculated separately as the prespecified performance measure at each post-baseline assessment minus its corresponding baseline measure. |
| Secondary | Change From Baseline in Digit Span Test (DST) Scores | Baseline, week 24 (end of treatment), and three months after completion of treatment | Attention and working memory will be assessed using the Digit Span Test (DST). Changes will be calculated separately as each prespecified score at each post-baseline assessment minus its corresponding baseline score. |
| Secondary | Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score | Baseline, week 24 (end of treatment), and three months after completion of treatment | Neuropsychiatric symptoms will be assessed using the Neuropsychiatric Inventory (NPI). Changes will be calculated separately as the total score at each post-baseline assessment minus the baseline total score. Higher scores indicate more severe neuropsychiatric symptoms; negative changes indicate improvement. |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests4
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Digit Span Test | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
| Verbal Learning | Secondary outcome | ConductCognition |
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07891650
GET https://conductscience.org/api/trials/v1/NCT07891650/registered